{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:32Z","timestamp":1788581552238,"version":"build-2803163510"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,4]]},"DOI":"10.1248\/bpb.b26-00050","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:12:10Z","timestamp":1788473530000},"page":"1425-1437","source":"Crossref","is-referenced-by-count":0,"title":["Body Mass Index-Related Trends in Adverse Events with Enfortumab Vedotin: Analysis of a Pharmacovigilance Database and Medical Records"],"prefix":"10.1248","volume":"49","author":[{"given":"Motoki","family":"Kei","sequence":"first","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204\u20138588, Japan"},{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Adachi Medical Center, 4\u201333\u20131 Kohoku, Adachi-ku, Tokyo 123\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Adachi Medical Center, 4\u201333\u20131 Kohoku, Adachi-ku, Tokyo 123\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Yamaga","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Adachi Medical Center, 4\u201333\u20131 Kohoku, Adachi-ku, Tokyo 123\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Karaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Adachi Medical Center, 4\u201333\u20131 Kohoku, Adachi-ku, Tokyo 123\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[{"name":"Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204\u20138588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Adachi Medical Center, 4\u201333\u20131 Kohoku, Adachi-ku, Tokyo 123\u20138558, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MT. Case report: enfortumab vedotin for metastatic urothelial carcinoma: a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction. <i>Front. Oncol.<\/i>, <b>11<\/b>, 621591 (2021).","DOI":"10.3389\/fonc.2021.621591"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Maguire WF, Lee D, Weinstock C, Gao X, Bulik CC, Agrawal S, Chang E, Hamed SS, Bloomquist EW, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL. FDA approval summary: enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or metastatic urothelial carcinoma. <i>Clin. Cancer Res.<\/i>, <b>30<\/b>, 2011\u20132016 (2024).","DOI":"10.1158\/1078-0432.c.7234923"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Challita-Eid PM, Satpayev D, Yang P, <i>et al<\/i>. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. <i>Cancer Res.<\/i>, <b>76<\/b>, 3003\u20133013 (2016).","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"4","unstructured":"4) Astellas Pharma Inc. \u201cPADCEV<sup>\u00ae<\/sup> for intravenous infusion 30 mg, package insert, 8th ed.\u201d: \u2039https:\/\/amn.astellas.jp\/di\/detail\/pev\/index_pev-30\u203a, accessed 25 August, 2025."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncol.<\/i>, <b>22<\/b>, 872\u2013882 (2021).","DOI":"10.1016\/S1470-2045(21)00094-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lacouture ME, Patel AB, Rosenberg JE, O\u2019Donnell PH. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. <i>Oncologist<\/i>, <b>27<\/b>, e223\u2013e232 (2022).","DOI":"10.1093\/oncolo\/oyac001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Nishihara K, Kurose H, Ito N, Ohnishi S, Hirano T, Suekane H, Watanabe K, Chikui K, Ueda K, Uemura KI, Nakiri M, Suekane S, Igawa T. Efficacy and safety of enfortumab vedotin in advanced urothelial carcinoma treatment: an initial experience in a single institution. <i>Nihon Hinyokika Gakkai Zasshi<\/i>, <b>115<\/b>, 21\u201327 (2024).","DOI":"10.5980\/jpnjurol.115.21"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nguyen MN, Reyes M, Jones SC. Postmarketing cases of enfortumab vedotin-associated skin reactions reported as Stevens\u2013Johnson syndrome or toxic epidermal necrolysis. <i>JAMA Dermatol.<\/i>, <b>157<\/b>, 1237\u20131239 (2021).","DOI":"10.1001\/jamadermatol.2021.3450"},{"key":"9","unstructured":"9) Suda F, Yamada T, Muto M, Korenaga Y. A case of toxic epidermal necrolysis-like cutaneous adverse reaction caused by enfortumab vedotin. <i>Rinsho Hifuka<\/i>, <b>78<\/b>, 489\u2013493 (2024). https:\/\/imis.igaku-shoin.co.jp\/journal\/412\/78\/7\/1412207337\/."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: the UROKYU study. <i>Anticancer Res.<\/i>, <b>44<\/b>, 3025\u20133032 (2024).","DOI":"10.21873\/anticanres.17115"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Matsuzawa Y, Tokunaga K, Kotani K, Keno Y, Kobayashi T, Tarui S. Simple estimation of ideal body weight from body mass index with the lowest morbidity. <i>Diabetes Res. Clin. Pract.<\/i>, <b>10<\/b> (Suppl 1), 159\u2013164 (1990).","DOI":"10.1016\/0168-8227(90)90157-O"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vlachou E, Matoso A, McConkey D, Jing Y, Johnson BA 3rd, Hahn NM, Hoffman-Censits J. Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature. <i>Eur. Urol. Open Sci.<\/i>, <b>49<\/b>, 100\u2013103 (2023).","DOI":"10.1016\/j.euros.2023.01.002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T. Steroid premedication impact on efficacy and cutaneous toxicity of enfortumab vedotin for advanced urothelial carcinoma. <i>In Vivo<\/i>, <b>39<\/b>, 1607\u20131614 (2025).","DOI":"10.21873\/invivo.13961"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Vlachou E, Johnson BA 3rd, McConkey D, Jing Y, Matoso A, Hahn NM, Hoffman-Censits J. Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience. <i>Front. Oncol.<\/i>, <b>14<\/b>, 1377842 (2024).","DOI":"10.3389\/fonc.2024.1377842"},{"key":"15","unstructured":"15) Pharmaceuticals and Medical Devices Agency. \u201cInformation on suspected adverse drug reaction reports.\u201d: \u2039https:\/\/www.info.pmda.go.jp\/fsearchnew\/jsp\/menu_fukusayou_attention_2.jsp\u203a, accessed 25 August, 2025."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Watanabe H, Matsushita Y, Watanabe A, Maeda T, Nukui K, Ogawa Y, Sawa J, Maeda H. Early detection of important safety information: recent methods for signal detection. <i>Jpn. J. Biomet.<\/i>, <b>25<\/b>, 37\u201360 (2004).","DOI":"10.5691\/jjb.25.37"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. <i>Am. J. Epidemiol.<\/i>, <b>151<\/b>, 531\u2013539 (2000).","DOI":"10.1093\/oxfordjournals.aje.a010240"},{"key":"18","unstructured":"18) MedDRA Japanese Maintenance Organization. \u201cMedical Dictionary for Regulatory Activities.\u201d: \u2039https:\/\/www.meddra.org\/\u203a, accessed 16 September, 2025."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Hosoya R, Uesawa Y, Ishii-Nozawa R, Kagaya H. Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database. <i>PLoS ONE<\/i>, <b>12<\/b>, e0172057 (2017).","DOI":"10.1371\/journal.pone.0172057"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kawabe A, Uesawa Y. Analysis of corticosteroid-induced glaucoma using the Japanese adverse drug event reporting database. <i>Pharmaceuticals<\/i>, <b>16<\/b>, 948 (2023).","DOI":"10.3390\/ph16070948"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Okunaka M, Kano D, Matsui R, Kawasaki T, Uesawa Y. Comprehensive analysis of chemotherapeutic agents that induce infectious neutropenia. <i>Pharmaceuticals<\/i>, <b>14<\/b>, 681 (2021).","DOI":"10.3390\/ph14070681"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kan Y, Nagai J, Uesawa Y. Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database. <i>Sci. Rep.<\/i>, <b>11<\/b>, 9625 (2021).","DOI":"10.1038\/s41598-021-88958-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Nakao Y, Asada M, Uesawa Y. Comprehensive study of drug-induced pruritus based on adverse drug reaction report database. <i>Pharmaceuticals<\/i>, <b>16<\/b>, 1500 (2023).","DOI":"10.3390\/ph16101500"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Chen JJ, Wang SJ, Tsai CA, Lin CJ. Selection of differentially expressed genes in microarray data analysis. <i>Pharmacogenomics J.<\/i>, <b>7<\/b>, 212\u2013220 (2007).","DOI":"10.1038\/sj.tpj.6500412"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Liu Q, Cui Z, Deng C, Yang C, Shi T. A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. <i>Front. Pharmacol.<\/i>, <b>15<\/b>, 1485190 (2024).","DOI":"10.3389\/fphar.2024.1485190"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lu Z, Suzuki A, Wang D. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions. <i>BMC Med. Res. Methodol.<\/i>, <b>23<\/b>, 71 (2023).","DOI":"10.1186\/s12874-023-01885-w"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Dobner J, Kaser S. Body mass index and the risk of infection\u2014from underweight to obesity. <i>Clin. Microbiol. Infect.<\/i>, <b>24<\/b>, 24\u201328 (2018).","DOI":"10.1016\/j.cmi.2017.02.013"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Phung DT, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: a systematic review and meta-analysis. <i>Obes. Rev.<\/i>, <b>14<\/b>, 839\u2013857 (2013).","DOI":"10.1111\/obr.12055"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Bourke CD, Berkley JA, Prendergast AJ. Immune dysfunction as a cause and consequence of malnutrition. <i>Trends Immunol.<\/i>, <b>37<\/b>, 386\u2013398 (2016).","DOI":"10.1016\/j.it.2016.04.003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Jans\u00e5ker F, Forsberg PO, Li X, Sundquist K. The relation of body mass index, body height, and parity to pyelonephritis: a nationwide population-based cohort study of over one million parous women (1997\u20132018). <i>Int. J. Infect. Dis.<\/i>, <b>125<\/b>, 67\u201373 (2022).","DOI":"10.1016\/j.ijid.2022.10.022"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Zhu T, Yang S, Mauro TM, Man MQ. Association of epidermal biophysical properties with obesity and its implications. <i>Skin Pharmacol. Physiol.<\/i>, <b>36<\/b>, 165\u2013173 (2023).","DOI":"10.1159\/000533587"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Horikawa T, Hiramoto K, Tanaka S, Ooi K. Skin dryness induced in the KK-Ay\/TaJcl type 2 diabetes mouse model deteriorates following dapagliflozin administration. <i>Biol. Pharm. Bull.<\/i>, <b>45<\/b>, 934\u2013939 (2022).","DOI":"10.1248\/bpb.b22-00241"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Wang HW, Hochberg AM, Pearson RK, Hauben M. An experimental investigation of masking in the US FDA adverse event reporting system database. <i>Drug Saf.<\/i>, <b>33<\/b>, 1117\u20131133 (2010).","DOI":"10.2165\/11584390-000000000-00000"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. <i>Drug Saf.<\/i>, <b>35<\/b>, 855\u2013864 (2012).","DOI":"10.2165\/11631780-000000000-00000"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Poleksic A, Xie L. Database of adverse events associated with drugs and drug combinations. <i>Sci. Rep.<\/i>, <b>9<\/b>, 20025 (2019).","DOI":"10.1038\/s41598-019-56525-5"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00050\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:27:38Z","timestamp":1788578858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00050\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00050","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"b26-00050"}}